Harrow, Inc. (HROW) Stock Analysis and Metrics

Harrow

NASDAQ: HROW

$38.48 ▼ -3.40 (-8.12%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.43 Bn

P/E-127.93

P/S5.33

Div. Yield0.00

Total Debt (Qtr)292.09 Mn

Revenue Growth (1y) (Qtr)-7.59

Add ratio to table…

About

Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America. The company develops, acquires, and markets FDA-approved ophthalmic pharmaceuticals and operates a compounding pharmacy business to address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and various ocular surface and retina diseases.

Harrow generates revenue primarily from the sale of its branded ophthalmic products, including IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, VERKAZIA, NEVANAC, FRESHKOTE, MAXITROL, MAXIDEX, and IOPIDINE, as well as from upcoming launches of BYOOVIZ, OPUVIZ, and BYQLOVI. Revenue also comes from its ImprimisRx compounding operations, which provide customized formulations to eye care professionals, and from out-licensing agreements and royalties on certain products.

The company operates through the following segments.

• Branded: This segment includes activities of FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of its products, and markets and sells treatments for anterior and posterior segment conditions such as IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, VERKAZIA, NEVANAC, FRESHKOTE, MAXITROL, MAXIDEX, and IOPIDINE.

• ImprimisRx: This segment represents the ophthalmology-focused pharmaceutical compounding business, providing customized formulations, combination therapies, alternative dosage strengths, and preservative-free formulations from its 503A pharmacy and 503B outsourcing facility in New Jersey to over 10,000 U. S. eye care prescribers and institutions.

Harrow competes with large branded and generic pharmaceutical companies, biosimilar manufacturers, and other firms developing ophthalmic therapies. While some competitors possess greater financial, technical, manufacturing, and commercial resources, Harrow differentiates itself through a focused portfolio of niche branded products and a compounding business that addresses unmet clinical needs. Its competitive advantages include a deep understanding of ophthalmic disease management, a pipeline of late-stage assets such as MELT-300, and the ability to offer both proprietary and compounded solutions to eye care providers.

Harrow serves ophthalmologists, optometrists, ambulatory surgery centers, hospitals, and other eye care professionals throughout the United States.

Investment Thesis

▲ Bull case

Harrow's underlying demand fundamentals remain exceptionally strong despite the Q1 VEVYE gross-to-net modeling issue, with new prescription growth up 25% sequentially and total prescriptions up 11% in Q1, achieved with fewer than 50 representatives before the sales force expansion. This performance occurred while the branded dry eye market declined 18%, indicating Harrow is gaining share in an expanding category that has grown 20% year-over-year for the last two years. The company's ability to grow prescriptions in a down market with a lean sales force demonstrates underlying product strength and commercial execution efficiency that will amplify as the doubled VEVYE team penetrates uncovered and underserved territories starting in Q2.
The commercial infrastructure investments are now complete and positioned to convert accelerating demand into sustained revenue growth, with Harrow having doubled its VEVYE sales force, tripled its TRIESENCE team, and bolstered Access+ and specialty teams for VERKAZIA and NATACYN. This expanded organization, built on recruited ophthalmic-experienced talent, is already showing early signs of impact with higher highs and higher lows in new prescription volumes and breaking demand trend lines to the upside in Q2. The company's focus on economic accomplishment over mere activity means this commercial engine will drive profitable growth as demand converts to revenue, supported by improving refill and reorder rates at or above internal estimates across core products.
Multiple high-conviction catalysts are set to drive acceleration in the second half of 2026 and beyond, including the July 1 commercial launch of BYOOVIZ (a best-in-class topical steroid with sampling already underway), the permanent J-code for IOPIDINE 1% enabling reimbursement in a laser procedure market exceeding 1.5 million annual use cases, approximately 20-25% net pricing improvement for IHEEZO with multiunit packaging launching in Q3, and upcoming clinical milestones for IHEEZO including initial retina data at ASRS in July and top-line QUELL study results in Q4. These drivers are independent of VEVYE's recovery and will contribute meaningfully to revenue growth, with IOPIDINE leveraging existing IHEEZO commercial relationships for rapid adoption.
Harrow is reaffirming its full-year 2026 revenue guidance of $350 million to $365 million despite the Q1 VEVYE headwind, signaling confidence in underlying demand trends and the strength of its diversified portfolio. The company's unified corporate initiative to achieve $250 million in quarterly revenue by end-2027 is underpinned by large, underpenetrated markets for its core products (VEVYE, IHEEZO, TRIESENCE) that represent durable growth platforms rather than short-cycle opportunities. With awareness building, new account starts accelerating, and breadth and depth within accounts expanding, Harrow is positioned to capture sustained value as its commercial investments fully translate into financial results in the back half of 2026 and into 2027.

Harrow's underlying demand fundamentals remain exceptionally strong despite the Q1 VEVYE gross-to-net modeling issue, with new prescription growth up 25% sequentially and total prescriptions up 11% in Q1, achieved with fewer than 50 representatives before the sales force expansion. This performance occurred while the branded dry eye market declined 18%, indicating Harrow is gaining share in an expanding category that has grown 20% year-over-year for the last two years. The company's ability to grow prescriptions in a down market with a lean sales force demonstrates underlying product strength and commercial execution efficiency that will amplify as the doubled VEVYE team penetrates uncovered and underserved territories starting in Q2.
The commercial infrastructure investments are now complete and positioned to convert accelerating demand into sustained revenue growth, with Harrow having doubled its VEVYE sales force, tripled its TRIESENCE team, and bolstered Access+ and specialty teams for VERKAZIA and NATACYN. This expanded organization, built on recruited ophthalmic-experienced talent, is already showing early signs of impact with higher highs and higher lows in new prescription volumes and breaking demand trend lines to the upside in Q2. The company's focus on economic accomplishment over mere activity means this commercial engine will drive profitable growth as demand converts to revenue, supported by improving refill and reorder rates at or above internal estimates across core products.
Multiple high-conviction catalysts are set to drive acceleration in the second half of 2026 and beyond, including the July 1 commercial launch of BYOOVIZ (a best-in-class topical steroid with sampling already underway), the permanent J-code for IOPIDINE 1% enabling reimbursement in a laser procedure market exceeding 1.5 million annual use cases, approximately 20-25% net pricing improvement for IHEEZO with multiunit packaging launching in Q3, and upcoming clinical milestones for IHEEZO including initial retina data at ASRS in July and top-line QUELL study results in Q4. These drivers are independent of VEVYE's recovery and will contribute meaningfully to revenue growth, with IOPIDINE leveraging existing IHEEZO commercial relationships for rapid adoption.
Harrow is reaffirming its full-year 2026 revenue guidance of $350 million to $365 million despite the Q1 VEVYE headwind, signaling confidence in underlying demand trends and the strength of its diversified portfolio. The company's unified corporate initiative to achieve $250 million in quarterly revenue by end-2027 is underpinned by large, underpenetrated markets for its core products (VEVYE, IHEEZO, TRIESENCE) that represent durable growth platforms rather than short-cycle opportunities. With awareness building, new account starts accelerating, and breadth and depth within accounts expanding, Harrow is positioned to capture sustained value as its commercial investments fully translate into financial results in the back half of 2026 and into 2027.

▼ Bear case

Harrow's Q1 revenue decline of $8 million tied to VEVYE gross-to-net pressures reveals a critical flaw in its commercial modeling and patient mix forecasting, particularly for high-deductible commercial plans where out-of-pocket buydowns were 40% higher than anticipated for CVS patients. Although management claims the issue is isolated to Q1 and has been corrected via business rule adjustments, the reliance on mid-April claims data to detect the problem indicates a significant lag in real-time visibility into payer-driven pricing dynamics, raising concerns about the company's ability to swiftly adapt to future shifts in commercial coverage terms or patient utilization patterns that could repeatedly impact net revenue.
The IHEEZO business remains heavily dependent on channel inventory dynamics and seasonal weakness, with Q2 revenue expected to remain muted due to residual channel stock from Q4 2025 and the loss of pass-through revenue, despite strong underlying unit demand growth of 18% year-over-year and new account increases of 21% sequentially. Management's expectation that revenue normalization will not occur until Q3 or Q4, contingent on the launch of multiunit packaging and net pricing improvements, suggests a prolonged drag on top-line performance from this core growth driver, especially as the company acknowledges that even Q2 IHEEZO revenue will not match prior year levels, delaying the conversion of strong demand into recognizable sales.
While Harrow highlights expanding sales forces across VEVYE (doubled), TRIESENCE (tripled), and specialty teams for VERKAZIA and NATACYN, the rapid hiring of approximately 100 new representatives in a short period introduces execution risks related to training, territory coverage, and productivity ramp-up, particularly given that early signs of impact are based on only a few weeks of field activity. The company's reliance on new rep deployment to drive accelerated growth assumes seamless integration and immediate effectiveness, yet ophthalmic sales cycles are inherently long due to physician adoption barriers and formulary processes, meaning the full financial benefit of this expanded commercial infrastructure may not materialize as quickly or as substantially as modeled, especially if rep turnover or underperformance occurs in the initial deployment phase.
The upcoming J-code for IOPIDINE 1%, while a positive reimbursement development, may deliver only incremental contribution in 2026 and meaningful impact primarily in 2027, as management explicitly tempered expectations by noting the launch will be incremental this year with bigger numbers anticipated in 2027. Given that Harrow's 2026 revenue guidance already assumes acceleration in the second half from multiple VEVYE-driven catalysts (sales force expansion, coverage realization, BYOOVIZ launch), any delay or underperformance in IOPIDINE adoption—despite its alignment with IHEEZO commercial calls—could undermine the credibility of the back-half growth thesis, particularly if physician behavior change is slower than anticipated due to entrenched use of off-label alternatives within capitated fee structures even after J-code availability.

Harrow's Q1 revenue decline of $8 million tied to VEVYE gross-to-net pressures reveals a critical flaw in its commercial modeling and patient mix forecasting, particularly for high-deductible commercial plans where out-of-pocket buydowns were 40% higher than anticipated for CVS patients. Although management claims the issue is isolated to Q1 and has been corrected via business rule adjustments, the reliance on mid-April claims data to detect the problem indicates a significant lag in real-time visibility into payer-driven pricing dynamics, raising concerns about the company's ability to swiftly adapt to future shifts in commercial coverage terms or patient utilization patterns that could repeatedly impact net revenue.
The IHEEZO business remains heavily dependent on channel inventory dynamics and seasonal weakness, with Q2 revenue expected to remain muted due to residual channel stock from Q4 2025 and the loss of pass-through revenue, despite strong underlying unit demand growth of 18% year-over-year and new account increases of 21% sequentially. Management's expectation that revenue normalization will not occur until Q3 or Q4, contingent on the launch of multiunit packaging and net pricing improvements, suggests a prolonged drag on top-line performance from this core growth driver, especially as the company acknowledges that even Q2 IHEEZO revenue will not match prior year levels, delaying the conversion of strong demand into recognizable sales.
While Harrow highlights expanding sales forces across VEVYE (doubled), TRIESENCE (tripled), and specialty teams for VERKAZIA and NATACYN, the rapid hiring of approximately 100 new representatives in a short period introduces execution risks related to training, territory coverage, and productivity ramp-up, particularly given that early signs of impact are based on only a few weeks of field activity. The company's reliance on new rep deployment to drive accelerated growth assumes seamless integration and immediate effectiveness, yet ophthalmic sales cycles are inherently long due to physician adoption barriers and formulary processes, meaning the full financial benefit of this expanded commercial infrastructure may not materialize as quickly or as substantially as modeled, especially if rep turnover or underperformance occurs in the initial deployment phase.
The upcoming J-code for IOPIDINE 1%, while a positive reimbursement development, may deliver only incremental contribution in 2026 and meaningful impact primarily in 2027, as management explicitly tempered expectations by noting the launch will be incremental this year with bigger numbers anticipated in 2027. Given that Harrow's 2026 revenue guidance already assumes acceleration in the second half from multiple VEVYE-driven catalysts (sales force expansion, coverage realization, BYOOVIZ launch), any delay or underperformance in IOPIDINE adoption—despite its alignment with IHEEZO commercial calls—could undermine the credibility of the back-half growth thesis, particularly if physician behavior change is slower than anticipated due to entrenched use of off-label alternatives within capitated fee structures even after J-code availability.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password